# 6-Aminonicotinamide enhances the efficacy of 5-aminolevulinic acid-mediated photodynamic therapy for neuroblastoma

**Authors:** Satoshi Muramatsu Okamura, Vipin Shankar Chelakkot, Zayar Linn, Yume Onishi, Kana Nakahata, Hidemi Toyoda, Hiroki Hori

PMC · DOI: 10.1186/s12885-025-15231-4 · 2025-11-25

## TL;DR

This study shows that combining 6-aminonicotinamide with photodynamic therapy improves treatment effectiveness in a type of childhood cancer called neuroblastoma.

## Contribution

The study introduces a novel combination therapy using 6-aminonicotinamide to enhance photodynamic therapy in MYCN-amplified neuroblastoma.

## Key findings

- 6-aminonicotinamide increased the cytotoxicity of photodynamic therapy in neuroblastoma cells.
- The combination therapy caused necrosis and lipid peroxidation in cancer cells.
- The treatment suppressed the glutathione redox system, increasing reactive oxygen species.

## Abstract

Photodynamic therapy (PDT) utilizing 5-aminolevulinic acid (5-ALA) as a photosensitizing precursor is an approved treatment modality for several types of cancers. However, the increased generation of antioxidants in cancer cells renders them resistant to PDT. MYCN-amplified neuroblastoma shows increased production of reactive oxygen species (ROS) and relies on the glutathione redox system for ROS detoxification. We tested the effectiveness of combining 6-aminonicotinamide (6-AN), a glucose-6-phosphate dehydrogenase inhibitor that modulates nicotinamide adenine dinucleotide phosphate and glutathione redox balance, with PDT for treating neuroblastoma.

Cellular protoporphyrin IX (PpIX) accumulation, cell proliferation, morphological changes, induction of cell death, redox status, and lipid peroxidation were evaluated in neuroblastoma cells treated with 5-ALA-mediated PDT with or without 6-AN.

6-AN enhanced cytotoxicity of 5-ALA-mediated PDT in MYCN-amplified neuroblastoma cells. The enhanced efficacy was attributed to the increase in intracellular PpIX along with the suppression of the glutathione redox system. An analysis of cell death mechanisms revealed that 5-ALA-mediated PDT combined with 6-AN induced necrosis with lipid peroxidation.

6-AN enhances the cytotoxicity of 5-ALA-mediated PDT and promotes membrane lipid peroxidation in neuroblastoma cells. 5-ALA-mediated PDT combined with 6-AN could be a potential treatment strategy for neuroblastoma.

The online version contains supplementary material available at 10.1186/s12885-025-15231-4.

## Linked entities

- **Genes:** MYCN (MYCN proto-oncogene, bHLH transcription factor) [NCBI Gene 4613]
- **Chemicals:** 6-aminonicotinamide (PubChem CID 9500), 5-aminolevulinic acid (PubChem CID 137), glutathione (PubChem CID 124886), protoporphyrin IX (PubChem CID 4971)
- **Diseases:** neuroblastoma (MONDO:0005072)

## Full-text entities

- **Genes:** G6PD (glucose-6-phosphate dehydrogenase) [NCBI Gene 2539] {aka CNSHA1, G6PD1}, MYCN (MYCN proto-oncogene, bHLH transcription factor) [NCBI Gene 4613] {aka FGLDS1, MODED, MPAPA, MYCNsORF, MYCNsPEP, N-myc}
- **Diseases:** necrosis (MESH:D009336), cancer (MESH:D009369), neuroblastoma (MESH:D009447), cytotoxicity (MESH:D064420)
- **Chemicals:** 5-ALA (MESH:C000614854), 6-AN (MESH:D015120), PpIX (MESH:C028025), lipid (MESH:D008055), glutathione (MESH:D005978), ROS (MESH:D017382), nicotinamide adenine dinucleotide phosphate (MESH:D009249)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12648907/full.md

---
Source: https://tomesphere.com/paper/PMC12648907